KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
about
Prognostic and predictive biomarkers: tools in personalized oncology.Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneityImpact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients.The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.BRAF gene: From human cancers to developmental syndromes.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran.High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer.Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patientsAn analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.Panitumumab : leading to better overall survival in metastatic colorectal cancer?Flexible lab-tailored cut-offs for suitability of formalin-fixed tumor samples for diagnostic mutational analyses.Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Improved detection of BRAF V600E using allele-specific PCR coupled with external and internal controllers.
P2860
Q33651583-A6D59409-80A9-448C-8672-62AB16AC40A0Q33732199-65EECA9E-7129-4A96-8934-AC4F90088959Q34206112-33E05CF0-C2A9-4C77-987D-0175977BE097Q34227451-79A7E921-9792-436B-BD20-6EE92911A5F4Q35125795-3C48DF01-C9F0-4729-A77D-AEE7E965AF01Q35802430-ECE2E52B-F46A-4592-9DB3-571CB8E7F8AFQ36012730-38795AD9-760A-456A-B0C7-235D390D67A0Q36229011-3A2D7BE9-C3E4-4449-831E-40932DFF252EQ36414198-75362E1D-AEFD-4A75-AF92-05EA7515EFBFQ37197507-2C713C78-C2C3-414F-BE31-1C0001C7D0E7Q37506582-E07D83CB-24B4-48A6-B8C4-CBC983BCFB67Q38193195-BF86AFD1-1973-4C77-867C-A5D2837E5608Q39284284-06BECC7C-4F5F-4D1D-B23D-665C3EBE1DECQ41418283-B3E39B09-DB0A-42B6-99A3-A11152F77F6DQ44504622-434F1027-B304-4460-8359-44A8EB44028B
P2860
KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
KRAS and BRAF mutation analysi ...... low percentage of tumor cells.
@en
type
label
KRAS and BRAF mutation analysi ...... low percentage of tumor cells.
@en
prefLabel
KRAS and BRAF mutation analysi ...... low percentage of tumor cells.
@en
P2860
P1476
KRAS and BRAF mutation analysi ...... low percentage of tumor cells
@en
P2093
Bogdan Żurawski
Marzena Anna Lewandowska
P2860
P2888
P304
P356
10.1007/S40291-013-0025-8
P577
2013-06-01T00:00:00Z